Hwang Sang-yeon, head of the private equity (PE) institutional sector at HB Investment and the designated CEO of Hanmi Pharmaceutical, has joined the board of directors of Hanmi Pharmaceutical.
At Hanmi Group headquarters in Songpa-gu, Seoul, on the 31st, all agenda items passed at Hanmi Pharmaceutical's regular shareholders meeting, including the appointment of Hwang Sang-yeon, the new CEO of Hanmi Pharmaceutical, as an inside director.
CEO Park Jae-hyun stepped down from the board, and the next CEO, Hwang Sang-yeon, newly joined the board.
The CEO-designate Hwang is a finance and investment expert who has served as head of a securities firm research center and as chief investment officer at a global asset management firm, and it is the first time in 53 years since its founding that an outsider will serve as CEO of Hanmi Pharmaceutical.
Starting with this shareholders meeting, the board of Hanmi Pharmaceutical has been newly reorganized. In the agenda for director appointments, Hwang Sang-yeon and Kim Na-young were appointed as inside directors, and Han Tae-joon and Kim Tae-yoon were appointed as outside directors.
Outside director Kim Tae-yoon was appointed as a Commissioner of the audit committee, and outside director Chae Yi-bae was newly appointed as an outside director who will serve as a Commissioner of the audit committee.
The National Pension Service also exercised its voting rights on this meeting's agenda. The National Pension Service cast a dissenting vote on the appointment of outside director Chae Yi-bae, saying the approval for post-retirement employment by the Public Service Ethics Committee had not been confirmed.
Agenda items such as partial amendments to the articles of incorporation, approval of the director compensation cap, and approval of plans to hold and dispose of treasury shares were also passed as originally proposed.